Accéder au contenu
Merck

Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures.

DNA research : an international journal for rapid publication of reports on genes and genomes (2015-09-02)
Tomokazu Amano, Emiko Jeffries, Misa Amano, Akihiro C Ko, Hong Yu, Minoru S H Ko
RÉSUMÉ

Aneuploidy, an abnormal number of chromosomes, has previously been considered irremediable. Here, we report findings that euploid cells increased among cultured aneuploid cells after exposure to the protein ZSCAN4, encoded by a mammalian-specific gene that is ordinarily expressed in preimplantation embryos and occasionally in stem cells. For footprint-free delivery of ZSCAN4 to cells, we developed ZSCAN4 synthetic mRNAs and Sendai virus vectors that encode human ZSCAN4. Applying the ZSCAN4 biologics to established cultures of mouse embryonic stem cells, most of which had become aneuploid and polyploid, dramatically increased the number of euploid cells within a few days. We then tested the biologics on non-immortalized primary human fibroblast cells derived from four individuals with Down syndrome—the most frequent autosomal trisomy of chromosome 21. Within weeks after ZSCAN4 application to the cells in culture, fluorescent in situ hybridization with a chromosome 21-specific probe detected the emergence of up to 24% of cells with only two rather than three copies. High-resolution G-banded chromosomes further showed up to 40% of cells with a normal karyotype. These findings were confirmed by whole-exome sequencing. Similar results were obtained for cells with the trisomy 18 of Edwards syndrome. Thus a direct, efficient correction of aneuploidy in human fibroblast cells seems possible in vitro using human ZSCAN4.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-ZSCAN4 antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution